Online Forums

Dr. Jens Grueger – an affiliate Professor at the University of Washington, Seattle, Sr. Advisor for BCG and Curta, and a past President of ISPOR – is a prominent global healthcare executive, and expert in health economics, pharmaceutical pricing, and market access strategies. He is widely recognized for his decades of leadership in both major pharmaceutical corporations and top-tier strategic consulting. Jens shared an up-to-date briefing on Most Favored Nation (MFN) policy and what it means for the Biopharma sector, especially what sustainability professionals need to know about MFN and what their role in these discussions could potentially be. The presentation was followed by a lively discussion under the Chatham House rule.

BSRT Advisory Panel member Christopher Greenwald's opening remarks highlighted the top-of-mind sustainability topics for the capital markets today, including AI scaling, Biopharma Innovation, Access to Medicines, and Human Capital, as well as systemic risks arising from Climate and Nature, and AMR. The conversation, with over 20 biopharma and investor representatives, also underlined business prerequisites for long-term value creation, such as solid Governance.

Companies are facing significant challenges as the global sustainability regulatory landscape shifts. Our 8th annual Regulatory and ESG Policy Outlook with the ECO:FACT team – Olivier Jaeggi, Managing Director, Alba González, Regulatory Advisory Lead, and Marta Barretta, Environmental Law Specialist – brought us up to date on regulatory changes in the EU, rollout of the ISSB reporting standards via national adoption, and growing legislative activity on forced labour and human rights. Emerging priorities, including Extended Producer Responsibility (EPR) and PFAS regulations were also addressed.

Klaus Moosmayer—former Chief Ethics, Risk & Compliance Officer at Novartis and now a Supervisory Board member at Deutsche Bank—joined our first BSRT Forum of 2026 to discuss the strategic value of sustainability and the need for integrated, cross-functional assurance to support effective Board oversight

Our 7th annual update with ECO:FACT on global ESG regulatory and policy developments affecting the Biopharma sector. Olivier Jaeggi, Managing Director and Chairman, Alba González, Senior ESG Expert, and Marta Barretta, Environmental Law Specialist, focus on topics where ESG policy and regulation are evolving, and what’s coming in the global pipeline of ESG regulations that will impact biopharma companies directly or indirectly.

Biopharma–Investor sustainability communications: 2025 state-of-play — Roundtable discussion with biopharma and investor representatives regarding the content and process of sustainability communications, plus early feedback on the updated Biopharma Investor ESG Communications Guidance 5.0.

TISFD is a global initiative to develop recommendations and guidance for businesses and financial institutions to understand and report on impacts, dependencies, risks, and opportunities related to people. They recently began work towards a future disclosure framework and guidance, including metrics and indicators. Simon Rawson, TISFD’s Executive Director, shared their plans and progress with the BSRT community, with a lively discussion following.

New biosynthetic methods and a recent USP equivalence ruling are driving the move away from Horseshoe Crab blood-derived testing reagents—impacting biodiversity, innovation, and supply chains. Jay Bolden (Eli Lilly), Adele Cheli (GSK), and Ryan Phelan (Revive & Restore) shared their work making this change happen and previewed the new Horseshoe Crab Scorecard.

A conversation with the Co-founder and Co-CEO of EcoVadis, Pierre-François Thaler. EcoVadis was founded in 2007 and has grown into a globally trusted provider of business sustainability ratings, with a network of more than 150,000 rated companies. Pierre-François and team will give insights into their assessment approach, and – very timely – their talks with the European Union regarding the CSDDD.